Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone
Tóm tắt
Introduction Luteinizing hormone-releasing hormone (LHRH) agonists (e.g., triptorelin) reduce ovarian estrogen production in premenopausal women with hormone-sensitive breast cancer. Aromatase inhibitors (e.g., exemestane) inhibit extraovarian production of estrogen and may further reduce circulating estrogens when combined with an LHRH agonist. Methods Healthy premenopausal women were randomized to receive 3.75 mg triptorelin (T) on days 1 and 29 with 25 mg exemestane (EX) or matched placebo once daily for 8 weeks, from day 1 to day 56. The primary objective was to evaluate the effect of T ± EX on estradiol (E2) suppression by comparing the AUCday36–57 for the 2 treatments. Secondary objectives included evaluation of estrone (E1), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) suppression; effects of EX on the T-induced gonadotrophin and estrogen flare; pharmacokinetics (PK); and safety. Results Twenty-eight (14 in each arm) were evaluable for efficacy and PK. Mean plasma estrogen levels (AUCday36–57) were significantly lower for subjects who received T + EX than for subjects who received T alone (20.6 vs. 54.0 pg d/ml [−62%; P < 0.05], and 38.9 vs. 198.0 pg d/ml [−80%; P < 0.01] for E2 and E1, respectively). Coadministration of EX did not affect the initial flare or subsequent suppression of LH and FSH following the first dose of T, or the PK of T. Both treatments were well tolerated. Conclusions Coadministration of T and EX resulted in greater estrogen suppression than when T was given alone. These findings could translate into improved clinical outcomes for premenopausal breast cancer patients receiving LHRH agonists.
Tài liệu tham khảo
Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343–353
Johannessen DC, Engan T, Di Salle E et al (1997) Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3:1101–1108
Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751–757
Geisler J, King N, Anker G et al (1998) In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4:2089–2093
Brueggemeier RW, Hackett JC, Diaz-Cruz ES (2005) Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 26:331–345
Miller WR (2004) Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab 18:1–32
Lonning P, Pfister C, Martoni A, Zamagni C (2003) Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol 30:23–32
Kaufmann M, Bajetta E, Dirix LY et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18:1399–1411
AROMASIN® (exemestane) (2005) Full prescribing information. Pharmacia & Upjohn Co, Division of Pfizer Inc., New York, NY
Filicori M, Flamigni C, Cognigni G et al (1993) Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J Clin Endocrinol Metab 77:130–133
Bolton S (1990) Pharmaceutical statistics: practical and clinical applications, 2nd edn. Marcel Dekker Inc., New York, NY
Michaud LB, Jones KL, Buzdar AU (2001) Combination endocrine therapy in the management of breast cancer. Oncologist 6:538–546
Rody A, Loibl S, von Minckwitz G, Kaufmann M (2005) Use of goserelin in the treatment of breast cancer. Expert Rev Anticancer Ther 5:591–604
Dowsett M, Folkerd E, Doody D, Haynes B (2005) The biology of steroid hormones and endocrine treatment of breast cancer. Breast 14:452–457
Smith IE, Dowsett M, Yap YS et al (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24:2444–2447
National Comprehensive Cancer Network (2007) Clinical practice guidelines in oncology: breast cancer, Version 2, 2007. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Cited July 26, 2007
Celio L, Martinetti A, Ferrari L et al (1999) Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 19:2261–2268
Dowsett M, Doody D, Miall S et al (1999) Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 56:25–34
Forward DP, Cheung KL, Jackson L, Robertson JF (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590–594
Clemett D, Lamb HM (2000) Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 59:1279–1296
Dank M (2002) The role of aromasin in the hormonal therapy of breast cancer. Pathol Oncol Res 8:87–92
Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092
Paridaens R, Dirix L, Lohrisch C et al (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391–1398
Trelstar® Depot (triptorelin pamoate for injectable suspension) (2006) Full prescribing information. Watson Pharma, Inc., Corona, CA
Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A (2005) Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 23:1736–1750
Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 23:619–629